Vaping News

Velo Reduced Risk Demonstrated

The potential of Velo to be used as a cigarette alternative like vapes has been reinforced by innovative real-world study

Share on:
The potential of Velo to be used as a cigarette alternative like vapes has been reinforced by innovative real-world study. The study shows Velo consumers had significantly better results for several indicators linked to smoking-related diseases compared with smokers, providing important new data and adding to the weight of evidence that supports nicotine pouches and their potential for reduced harm.

New results from an innovative cross-sectional clinical study of Velo, BAT’s flagship modern oral nicotine pouch product, have been published in Biomarkers Journal. In the study, consumers exclusively using Velo for over six months had significant favourable differences in several biomarkers of exposure and biomarkers of potential harm relevant to smoking-related diseases compared to the adults who smoked. 

The results showed that the levels for the biomarkers of exposure, based on priority toxicants as defined by the WHO, were substantially lower in Velo consumers compared with smokers.  The data also showed favourable differences between the Velo consumers and smokers in the majority of the biomarkers of potential harm, with four achieving statistical significance, and the others having similar levels across the Velo consumers, former and never smoker groups.  

The study provides important new data and insights into the real-world health impact in Velo consumers compared to smokers, former smokers and never smokers.  A single set of samples of blood, urine and other clinical measurements was tested for certain toxicants and a range of biomarkers thought to be linked to the development of diseases such as cancer and cardiovascular disease (CVD). 

 Dr David O’Reilly, Director, Scientific Research at BAT, said: “These results are very important for Velo and the modern oral nicotine product category. They build on the extensive scientific evidence, including epidemiological data, that already exists for oral tobacco and add to the weight of evidence that supports our belief that Velo is a reduced-risk product for smokers who completely switch from cigarettes as compared to continued smoking.  We have already generated data that shows Velo has a toxicant profile better than snus and comparable to Nicotine Replacement Therapy (NRT). These results add further evidence that supports the important contribution Velo can make to Tobacco Harm Reduction.

“I’d like to thank everyone who participated and helped deliver this study. It is another important step forward in our journey to building A Better Tomorrow.”

  • Based on the biomarkers measured, compared to smokers, Velo consumers who had been using the product exclusively showed:
  • Significantly lower levels in biomarkers of exposure to priority tobacco toxicants
  • Significant favourable differences in a biomarker of potential harm relevant to lung cancer risk
  • Significant favourable differences in a number of biomarkers of potential harm relevant to cardiovascular disease
  • Significant favourable differences in a biomarker of potential harm relevant to general inflammation

For the biomarkers that showed no significant difference between the Velo consumers and smokers, similar levels were observed between the Velo and former and never smoker groups.


Dave Cross avatar

Dave Cross

Journalist at POTV
View Articles

Dave is a freelance writer; with articles on music, motorbikes, football, pop-science, vaping and tobacco harm reduction in Sounds, Melody Maker, UBG, AWoL, Bike, When Saturday Comes, Vape News Magazine, and syndicated across the Johnston Press group. He was published in an anthology of “Greatest Football Writing”, but still believes this was a mistake. Dave contributes sketches to comedy shows and used to co-host a radio sketch show. He’s worked with numerous vape companies to develop content for their websites.

Join the discussion

Vaping News

Harm Reduction For The Rich

The United Kingdom risks becoming a harm reduction country only for the wealthy, according to Michael Landl of the World Vapers’ Alliance

Vaping News

CAPHRA Highlights Tobacco Control Flaws

The Coalition of Asia Pacific Tobacco Harm Reduction Advocates highlights the flaws in tobacco control which has led to the rise of black market in Australia

Vaping News

A Missed Opportunity at COP10

The Smoke Free Sweden movement says that COP10 was a missed opportunity to save millions of lives

Vaping News

COP10: Promote Tobacco Harm Reduction

Experts with Smoke Free Sweden are emphasising the urgent need for a Tobacco Harm Reduction approach at COP10